Matthew Adamow

5.4k total citations · 1 hit paper
12 papers, 525 citations indexed

About

Matthew Adamow is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Matthew Adamow has authored 12 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Matthew Adamow's work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Matthew Adamow is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Matthew Adamow collaborates with scholars based in United States, Greece and Haiti. Matthew Adamow's co-authors include Katherine S. Panageas, Jianda Yuan, Jedd D. Wolchok, Teresa Rasalan, Deborah Kuk, Humilidad F. Gallardo, Brian Ginsberg, Stephanie Terzulli, Sacha Gnjatic and Ruth Halaban and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Matthew Adamow

12 papers receiving 510 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrated NY-ESO-1 antibody and CD8⁺T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

2011 254 citations Jianda Yuan, Matthew Adamow et al. Proceedings of the National Academy of Sciences profile →

Peers

Matthew Adamow

IMMUN

ONCOL

PRM

Mara Valentini Italy

Baukje‐Nynke Hoogeboom Netherlands

Hiep Khong United States

Pepijn G.J.T.B. Wijnands Netherlands

Kenzo Ohara Japan

Korina G. Veenstra United States

Miao-La Ke China

Özcan Met Denmark

Dries Renmans Belgium

Darin A. Wick Canada

Mara Valentini Italy

Matthew Adamow

450 ×1.1

IMMUN

379 ×1.1

ONCOL

125 ×1.0

27 ×0.9

38 ×1.2

PRM

Citations per year, relative to Matthew Adamow Matthew Adamow (= 1×) peers Mara Valentini

Countries citing papers authored by Matthew Adamow

Since Specialization

Citations

This map shows the geographic impact of Matthew Adamow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Adamow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Adamow more than expected).

Fields of papers citing papers by Matthew Adamow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Adamow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Adamow. The network helps show where Matthew Adamow may publish in the future.

Co-authorship network of co-authors of Matthew Adamow

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Adamow. A scholar is included among the top collaborators of Matthew Adamow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Adamow. Matthew Adamow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Rolig, Annah S., Melissa J. Kasiewicz, William L. Miller, et al.. (2025). The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming. Science Translational Medicine. 17(793). eadk3702–eadk3702. 4 indexed citations

Smithy, James W., Ronak Shah, Matthew Adamow, et al.. (2024). Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study. Clinical Cancer Research. 30(16). 3407–3415. 4 indexed citations

Tsimberidou, Apostolia M., Alexandra Drakaki, Danny N. Khalil, et al.. (2024). Abstract CT138: Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort. Cancer Research. 84(7_Supplement). CT138–CT138. 1 indexed citations

Adamow, Matthew, Colleen Maher, Michael A. Postow, et al.. (2023). A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy. Cell Reports Methods. 3(8). 100546–100546. 3 indexed citations

Price, Leah, Matthew Adamow, Sebastian Attig, et al.. (2020). Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI). Cytometry Part A. 99(1). 107–116. 6 indexed citations

Vorkas, Charles Kyriakos, Matthew F. Wipperman, Kelin Li, et al.. (2018). Mucosal-associated invariant and γδ T cell subsets respond to initial Mycobacterium tuberculosis infection. JCI Insight. 3(19). 50 indexed citations

Postow, Michael A., Deborah Kuk, Matthew Adamow, et al.. (2016). Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone.. Journal of Clinical Oncology. 34(15_suppl). 3073–3073. 2 indexed citations

Kitano, Shigehisa, Michael A. Postow, Carly G.K. Ziegler, et al.. (2014). Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. Cancer Immunology Research. 2(8). 812–821. 111 indexed citations

Yuan, Jianda, Geoffrey Y. Ku, Matthew Adamow, et al.. (2013). Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. Journal for ImmunoTherapy of Cancer. 1(1). 20–20. 38 indexed citations

10.

Castilla‐Llorente, Virginia, et al.. (2012). Mammalian GW220/TNGW1 is essential for the formation of GW/P bodies containing miRISC. The Journal of Cell Biology. 198(4). 529–544. 13 indexed citations

11.

Yuan, Jianda, Matthew Adamow, Brian Ginsberg, et al.. (2011). Integrated NY-ESO-1 antibody and CD8⁺T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences. 108(40). 16723–16728. 254 indexed citations breakdown →

12.

Ginsberg, Brian, Humilidad F. Gallardo, Teresa Rasalan, et al.. (2010). Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection. Clinical Cancer Research. 16(15). 4057–4065. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact